Report Details

The acute lymphoblastic leukemia market is set for rapid growth over the forecast period. In terms of revenue, the global acute lymphoblastic leukemia market accounted for USD 2,500 Million in 2019 and is expected to reach USD 3,500 Million by 2026, growing at a CAGR of 5.4%.

Global Acute Lymphoblastic Leukemia Market: Overview

Acute lymphoblastic leukemia (ALL) is a type of bone marrow and blood cancer. It is more common in children and if treated there is a good chance for curing it. It can also be found in adults however the chances of cure reduce in the case of adults. The ALL starts from the bone marrow where new blood cells are made. The leukemia cells can sometimes also spread to different parts of the body such as the spleen, testicles, liver, lymph nodes, and central nervous system.

Global Acute Lymphoblastic Leukemia Market: Growth Factors

The global acute lymphoblastic leukemia market is driven by technological advancements in the detection of affected cells. The growth of the market can also be attributed to the growing number of cases of bone marrow biopsies. The increasing number of cancer cases globally among the geriatric population is also anticipated to boost the market. Some of the drugs that are used in acute lymphoblastic leukemia are Cyclophosphamide by Baxter, Amsacrine by NordMedica, and Cytarabine by Pfizer. The development of new therapies is giving the market significant momentum. For instance, Novartis AG developed a novel cell therapy for Chimeric Antigen Receptor (CAR)-T cells. The novel therapy is anticipated to receive approval from FDA by 2020 and is currently in phase II clinical trials. Various initiatives are taken by the government and different organizations such as National Cancer Institute, American Cancer Society, and FNIH to fight against acute lymphoblastic leukemia. Based on data published in 2017 by the American Cancer Society, there were around 3,350 males and 2,620 females diagnosed with acute lymphoblastic leukemia among which 800 males and 640 females were estimated to die from the condition.

Global Acute Lymphoblastic Leukemia Market: Segmentation

The global acute lymphoblastic leukemia market is segmented into its type, therapy type, drug, and regions. On the basis of the type, the global market is segregated into adults and pediatrics. Based on the therapy type, the market is bifurcated into targeted therapy, stem cell transplantation, chemotherapy, and radiation therapy. On the basis of drugs, the global market is segmented into linker regimen, targeted drugs & immunotherapy, oncaspar, hyper-CVAD regimen, nucleoside metabolic inhibitors, CALGB 8811 regimen, and others. Geographically, the global acute lymphoblastic leukemia market is diversified into North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa.

Global Acute Lymphoblastic Leukemia Market: Regional Analysis

North America region dominated the global acute lymphoblastic leukemia market in 2019 and is anticipated to continue its dominance in the upcoming years. The dominance of the North America market can be attributed to the presence of key players in the region, easy accessibility of diagnosis, and high treatment cost. The Asia Pacific region is anticipated to grow at the highest rate in the forecast period owing to the rising population in the region and increasing awareness of the population towards cancer treatment.

Global Acute Lymphoblastic Leukemia Market: Competitive Players

Some of the key players in the acute lymphoblastic leukemia market are Celegene Corporation, Erytech Pharma, Genmab A/S, Novartis AG, Sanofi SA, Bristol Myer Squibb Company, Eisai Co Ltd, Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, and Pfizer Inc. among others. 

Global Acute Lymphoblastic Leukemia Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1 Executive Summary
    • 1.1. Introduction of Acute Lymphoblastic Leukemia
    • 1.2. Global Acute Lymphoblastic Leukemia Market, 2019 & 2026 (USD Million)
    • 1.3. Global Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
    • 1.4. Global Acute Lymphoblastic Leukemia Market Absulute Revenue Opportunity, 2016 – 2026 (USD Million)
    • 1.5. Global Acute Lymphoblastic Leukemia Market Incremental Revenue Opportunity, 2020 – 2026 (USD Million)
  • Chapter 2 Acute Lymphoblastic Leukemia Market – Type Analysis
    • 2.1. Global Acute Lymphoblastic Leukemia Market – Type Overview
    • 2.2. Global Acute Lymphoblastic Leukemia Market Share, by Type, 2019 & 2026 (USD Million)
    • 2.3. Pediatrics
      • 2.3.1. Global Pediatrics Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
    • 2.4. Adults
      • 2.4.1. Global Adults Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
  • Chapter 3 Acute Lymphoblastic Leukemia Market – Therapy Type Analysis
    • 3.1. Global Acute Lymphoblastic Leukemia Market – Therapy Type Overview
    • 3.2. Global Acute Lymphoblastic Leukemia Market Share, by Therapy Type, 2019 & 2026 (USD Million)
    • 3.3. Chemotherapy
      • 3.3.1. Global Chemotherapy Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
    • 3.4. Targeted Therapy
      • 3.4.1. Global Targeted Therapy Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
    • 3.5. Radiation Therapy
      • 3.5.1. Global Radiation Therapy Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
    • 3.6. Stem Cell Transplantation
      • 3.6.1. Global Stem Cell Transplantation Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
  • Chapter 4 Acute Lymphoblastic Leukemia Market – Drug Analysis
    • 4.1. Global Acute Lymphoblastic Leukemia Market – Drug Overview
    • 4.2. Global Acute Lymphoblastic Leukemia Market Share, by Drug, 2019 & 2026 (USD Million)
    • 4.3. Hyper-CVAD Regimen
      • 4.3.1. Global Hyper-CVAD Regimen Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
    • 4.4. Linker Regimen
      • 4.4.1. Global Linker Regimen Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
    • 4.5. Nucleoside Metabulic Inhibitors
      • 4.5.1. Global Nucleoside Metabulic Inhibitors Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
    • 4.6. Targeted Drugs & Immunotherapy
      • 4.6.1. Global Targeted Drugs & Immunotherapy Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
    • 4.7. CALGB 8811 Regimen
      • 4.7.1. Global CALGB 8811 Regimen Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
    • 4.8. Oncaspar
      • 4.8.1. Global Oncaspar Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
    • 4.9. Others
      • 4.9.1. Global Others Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
  • Chapter 5 Acute Lymphoblastic Leukemia Market – Regional Analysis
    • 5.1. Global Acute Lymphoblastic Leukemia Market Regional Overview
    • 5.2. Global Acute Lymphoblastic Leukemia Market Share, by Region, 2019 & 2026 (USD Million)
    • 5.3. North America
      • 5.3.1. North America Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
        • 5.3.1.1. North America Acute Lymphoblastic Leukemia Market, by Country, 2016 - 2026 (USD Million)
      • 5.3.2. North America Acute Lymphoblastic Leukemia Market, by Type, 2016 – 2026
        • 5.3.2.1. North America Acute Lymphoblastic Leukemia Market, by Type, 2016 – 2026 (USD Million)
      • 5.3.3. North America Acute Lymphoblastic Leukemia Market, by Therapy Type, 2016 – 2026
        • 5.3.3.1. North America Acute Lymphoblastic Leukemia Market, by Therapy Type, 2016 – 2026 (USD Million)
      • 5.3.4. North America Acute Lymphoblastic Leukemia Market, by Drug, 2016 – 2026
        • 5.3.4.1. North America Acute Lymphoblastic Leukemia Market, by Drug, 2016 – 2026 (USD Million)
      • 5.3.5. U.S.
        • 5.3.5.1. U.S. Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
      • 5.3.6. Canada
        • 5.3.6.1. Canada Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
    • 5.4. Europe
      • 5.4.1. Europe Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
        • 5.4.1.1. Europe Acute Lymphoblastic Leukemia Market, by Country, 2016 - 2026 (USD Million)
      • 5.4.2. Europe Acute Lymphoblastic Leukemia Market, by Type, 2016 – 2026
        • 5.4.2.1. Europe Acute Lymphoblastic Leukemia Market, by Type, 2016 – 2026 (USD Million)
      • 5.4.3. Europe Acute Lymphoblastic Leukemia Market, by Therapy Type, 2016 – 2026
        • 5.4.3.1. Europe Acute Lymphoblastic Leukemia Market, by Therapy Type, 2016 – 2026 (USD Million)
      • 5.4.4. Europe Acute Lymphoblastic Leukemia Market, by Drug, 2016 – 2026
        • 5.4.4.1. Europe Acute Lymphoblastic Leukemia Market, by Drug, 2016 – 2026 (USD Million)
      • 5.4.5. Germany
        • 5.4.5.1. Germany Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
      • 5.4.6. France
        • 5.4.6.1. France Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
      • 5.4.7. U.K.
        • 5.4.7.1. U.K. Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
      • 5.4.8. Italy
        • 5.4.8.1. Italy Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
      • 5.4.9. Spain
        • 5.4.9.1. Spain Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
      • 5.4.10. Rest of Europe
        • 5.4.10.1. Rest of Europe Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
    • 5.5. Asia Pacific
      • 5.5.1. Asia Pacific Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
        • 5.5.1.1. Asia Pacific Acute Lymphoblastic Leukemia Market, by Country, 2016 - 2026 (USD Million)
      • 5.5.2. Asia Pacific Acute Lymphoblastic Leukemia Market, by Type, 2016 – 2026
        • 5.5.2.1. Asia Pacific Acute Lymphoblastic Leukemia Market, by Type, 2016 – 2026 (USD Million)
      • 5.5.3. Asia Pacific Acute Lymphoblastic Leukemia Market, by Therapy Type, 2016 – 2026
        • 5.5.3.1. Asia Pacific Acute Lymphoblastic Leukemia Market, by Therapy Type, 2016 – 2026 (USD Million)
      • 5.5.4. Asia Pacific Acute Lymphoblastic Leukemia Market, by Drug, 2016 – 2026
        • 5.5.4.1. Asia Pacific Acute Lymphoblastic Leukemia Market, by Drug, 2016 – 2026 (USD Million)
      • 5.5.5. China
        • 5.5.5.1. China Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
      • 5.5.6. Japan
        • 5.5.6.1. Japan Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
      • 5.5.7. India
        • 5.5.7.1. India Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
      • 5.5.8. South Korea
        • 5.5.8.1. South Korea Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
      • 5.5.9. South-East Asia
        • 5.5.9.1. South-East Asia Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
      • 5.5.10. Rest of Asia Pacific
        • 5.5.10.1. Rest of Asia Pacific Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
    • 5.6. Latin America
      • 5.6.1. Latin America Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
        • 5.6.1.1. Latin America Acute Lymphoblastic Leukemia Market, by Country, 2016 - 2026 (USD Million)
      • 5.6.2. Latin America Acute Lymphoblastic Leukemia Market, by Type, 2016 – 2026
        • 5.6.2.1. Latin America Acute Lymphoblastic Leukemia Market, by Type, 2016 – 2026 (USD Million)
      • 5.6.3. Latin America Acute Lymphoblastic Leukemia Market, by Therapy Type, 2016 – 2026
        • 5.6.3.1. Latin America Acute Lymphoblastic Leukemia Market, by Therapy Type, 2016 – 2026 (USD Million)
      • 5.6.4. Latin America Acute Lymphoblastic Leukemia Market, by Drug, 2016 – 2026
        • 5.6.4.1. Latin America Acute Lymphoblastic Leukemia Market, by Drug, 2016 – 2026 (USD Million)
      • 5.6.5. Brazil
        • 5.6.5.1. Brazil Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
      • 5.6.6. Mexico
        • 5.6.6.1. Mexico Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
      • 5.6.7. Rest of Latin America
        • 5.6.7.1. Rest of Latin America Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
    • 5.7. The Middle-East and Africa
      • 5.7.1. The Middle-East and Africa Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
        • 5.7.1.1. The Middle-East and Africa Acute Lymphoblastic Leukemia Market, by Country, 2016 - 2026 (USD Million)
      • 5.7.2. The Middle-East and Africa Acute Lymphoblastic Leukemia Market, by Type, 2016 – 2026
        • 5.7.2.1. The Middle-East and Africa Acute Lymphoblastic Leukemia Market, by Type, 2016 – 2026 (USD Million)
      • 5.7.3. The Middle-East and Africa Acute Lymphoblastic Leukemia Market, by Therapy Type, 2016 – 2026
        • 5.7.3.1. The Middle-East and Africa Acute Lymphoblastic Leukemia Market, by Therapy Type, 2016 – 2026 (USD Million)
      • 5.7.4. The Middle-East and Africa Acute Lymphoblastic Leukemia Market, by Drug, 2016 – 2026
        • 5.7.4.1. The Middle-East and Africa Acute Lymphoblastic Leukemia Market, by Drug, 2016 – 2026 (USD Million)
      • 5.7.5. GCC Countries
        • 5.7.5.1. GCC Countries Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
      • 5.7.6. South Africa
        • 5.7.6.1. South Africa Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
      • 5.7.7. Rest of Middle-East Africa
        • 5.7.7.1. Rest of Middle-East Africa Acute Lymphoblastic Leukemia Market, 2016 – 2026 (USD Million)
  • Chapter 6 Acute Lymphoblastic Leukemia Market – Competitive Landscape
    • 6.1. Competitor Market Share – Revenue
    • 6.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players
    • 6.3. Strategic Developments
      • 6.3.1. Acquisitions and Mergers
      • 6.3.2. New Products
      • 6.3.3. Research & Development Activities
  • Chapter 7 Company Profiles
    • 7.1. Bristul Myer Squibb Company
      • 7.1.1. Company Overview
      • 7.1.2. Product/Service Portfulio
      • 7.1.3. Bristul Myer Squibb Company Sales, Revenue, and Gross Margin
      • 7.1.4. Bristul Myer Squibb Company Revenue and Growth Rate
      • 7.1.5. Bristul Myer Squibb Company Market Share
      • 7.1.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 7.2. Celegene Corporation
      • 7.2.1. Company Overview
      • 7.2.2. Product/Service Portfulio
      • 7.2.3. Celegene Corporation Sales, Revenue, and Gross Margin
      • 7.2.4. Celegene Corporation Revenue and Growth Rate
      • 7.2.5. Celegene Corporation Market Share
      • 7.2.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 7.3. Eisai Co Ltd
      • 7.3.1. Company Overview
      • 7.3.2. Product/Service Portfulio
      • 7.3.3. Eisai Co Ltd Sales, Revenue, and Gross Margin
      • 7.3.4. Eisai Co Ltd Revenue and Growth Rate
      • 7.3.5. Eisai Co Ltd Market Share
      • 7.3.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 7.4. Erytech Pharma
      • 7.4.1. Company Overview
      • 7.4.2. Product/Service Portfulio
      • 7.4.3. Erytech Pharma Sales, Revenue, and Gross Margin
      • 7.4.4. Erytech Pharma Revenue and Growth Rate
      • 7.4.5. Erytech Pharma Market Share
      • 7.4.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 7.5. Hoffmann-La Roche Ltd
      • 7.5.1. Company Overview
      • 7.5.2. Product/Service Portfulio
      • 7.5.3. Hoffmann-La Roche Ltd Sales, Revenue, and Gross Margin
      • 7.5.4. Hoffmann-La Roche Ltd Revenue and Growth Rate
      • 7.5.5. Hoffmann-La Roche Ltd Market Share
      • 7.5.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 7.6. Genmab A/S
      • 7.6.1. Company Overview
      • 7.6.2. Product/Service Portfulio
      • 7.6.3. Genmab A/S Sales, Revenue, and Gross Margin
      • 7.6.4. Genmab A/S Revenue and Growth Rate
      • 7.6.5. Genmab A/S Market Share
      • 7.6.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 7.7. GlaxoSmithKline PLC
      • 7.7.1. Company Overview
      • 7.7.2. Product/Service Portfulio
      • 7.7.3. GlaxoSmithKline PLC Sales, Revenue, and Gross Margin
      • 7.7.4. GlaxoSmithKline PLC Revenue and Growth Rate
      • 7.7.5. GlaxoSmithKline PLC Market Share
      • 7.7.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 7.8. Novartis AG
      • 7.8.1. Company Overview
      • 7.8.2. Product/Service Portfulio
      • 7.8.3. Novartis AG Sales, Revenue, and Gross Margin
      • 7.8.4. Novartis AG Revenue and Growth Rate
      • 7.8.5. Novartis AG Market Share
      • 7.8.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 7.9. Pfizer Inc.
      • 7.9.1. Company Overview
      • 7.9.2. Product/Service Portfulio
      • 7.9.3. Pfizer Inc. Sales, Revenue, and Gross Margin
      • 7.9.4. Pfizer Inc. Revenue and Growth Rate
      • 7.9.5. Pfizer Inc. Market Share
      • 7.9.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 7.10. Sanofi SA
      • 7.10.1. Company Overview
      • 7.10.2. Product/Service Portfulio
      • 7.10.3. Sanofi SA Sales, Revenue, and Gross Margin
      • 7.10.4. Sanofi SA Revenue and Growth Rate
      • 7.10.5. Sanofi SA Market Share
      • 7.10.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
  • Chapter 8 Acute Lymphoblastic Leukemia — Industry Analysis
    • 8.1. Introduction and Taxonomy
    • 8.2. Acute Lymphoblastic Leukemia Market – Key Trends
      • 8.2.1. Market Drivers
      • 8.2.2. Market Restraints
      • 8.2.3. Market Opportunities
    • 8.3. Value Chain Analysis
    • 8.4. Key Mandates and Regulations
    • 8.5. Technulogy Roadmap and Timeline
    • 8.6. Acute Lymphoblastic Leukemia Market – Attractiveness Analysis
      • 8.6.1. By Type
      • 8.6.2. By Therapy Type
      • 8.6.3. By Drug
      • 8.6.4. By Region
  • Chapter 9 Industrial Chain, Sourcing Strategy, and Downstream Buyers
    • 9.1. Acute Lymphoblastic Leukemia Industrial Chain Analysis
    • 9.2. Downstream Buyers
    • 9.3. Distributors/Traders List
  • Chapter 10 Marketing Strategy Analysis
    • 10.1. Marketing Channel
    • 10.2. Direct Marketing
    • 10.3. Indirect Marketing
    • 10.4. Marketing Channel Development Trends
    • 10.5. Economic/Pulitical Environmental Change
  • Chapter 11 Report Conclusion & Key Insights
    • 11.1. Key Insights from Primary Interviews & Surveys Respondents
    • 11.2. Key Takeaways from Analysts, Consultants, and Industry Leaders
  • Chapter 12 Research Approach & Methodulogy
    • 12.1. Report Description
    • 12.2. Research Scope
    • 12.3. Research Methodulogy
      • 12.3.1. Secondary Research
      • 12.3.2. Primary Research
      • 12.3.3. Statistical Models
        • 12.3.3.1. Company Share Analysis Model
        • 12.3.3.2. Revenue Based Modeling
      • 12.3.4. Research Limitations

Inquiry For Buying

Acute Lymphoblastic Leukemia

Please fill out the form. We will contact you within 24 hours:
All fields required...

Request Sample

Acute Lymphoblastic Leukemia

Please fill out the form. We will contact you within 24 hours:
All fields required...
Inquiry For Buying

×

Avail Free PDF Sample Report

This website is secure and your personal details are safe. Privacy Policy

Thank you for contacting us.

Thank you for your interest in our research report.

We will be sending you the sample copy of the report shortly. Meanwhile, if you have any specific research requirement then please let us know. We will be glad to assist you in case you have any additional questions, so feel free to get in touch

Thank you


Warm regards,
Sales | Manager - International Business and partner Relations
Direct line: +1 347 535 0815
Market Research Store
E-mail: sales@MarketResearchStore.com | Web: www.MarketResearchStore.com